open access

Vol 78, No 1 (2010)
EDUCATION
Published online: 2010-01-29
Submitted: 2013-02-22
Get Citation

Antileukotriene drugs in the treatment of obstructive lung diseases and rhinitis

Lucyna Mastalerz, Aleksander Kania
Pneumonol Alergol Pol 2010;78(1):74-78.

open access

Vol 78, No 1 (2010)
EDUCATION
Published online: 2010-01-29
Submitted: 2013-02-22

Abstract

Recently published international recommendations including Global INitiative for Asthma, PRACTicing ALLergology and Allergic Rhinitis and its Impact on Asthma offer antileukotriene drugs for adult and childhood asthma and allergic rhinitis. In this article we discuss the arguments for and against antileukotriene drugs therapy in the treatment of obstructive lung diseases and rhinitis.

Abstract

Recently published international recommendations including Global INitiative for Asthma, PRACTicing ALLergology and Allergic Rhinitis and its Impact on Asthma offer antileukotriene drugs for adult and childhood asthma and allergic rhinitis. In this article we discuss the arguments for and against antileukotriene drugs therapy in the treatment of obstructive lung diseases and rhinitis.
Get Citation

Keywords

antileukotriene drugs; asthma; rhinitis

About this article
Title

Antileukotriene drugs in the treatment of obstructive lung diseases and rhinitis

Journal

Advances in Respiratory Medicine

Issue

Vol 78, No 1 (2010)

Pages

74-78

Published online

2010-01-29

Bibliographic record

Pneumonol Alergol Pol 2010;78(1):74-78.

Keywords

antileukotriene drugs
asthma
rhinitis

Authors

Lucyna Mastalerz
Aleksander Kania

References (42)
  1. INA Global Strategy for Asthma Management and Prevention, 2006 NHI Publications No 02-3659.
  2. Bacharier LB, Boner A, Carlsen KH, et al. European Pediatric Asthma Group. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy. 2008; 63(1): 5–34.
  3. Bisgaard H. Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med. 2003; 167(3): 379–383.
  4. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990; 323(10): 645–655.
  5. Adelroth E, Morris MM, Hargreave FE, et al. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med. 1986; 315(8): 480–484.
  6. Cloud ML, Enas GC, Kemp J, et al. A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis. 1989; 140(5): 1336–1339.
  7. Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med. 1994; 150(3): 618–623.
  8. Barnes NC, Black B, Syrett N, et al. Reduction of exacerbations of asthma in multinational clinical trials with zafirlukast (Accolate). Allergy. 1996(supl. 30): 84.
  9. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med. 1998; 158(11): 1213–1220.
  10. Israel E, Cohn J, Dubé L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA. 1996; 275(12): 931–936.
  11. Liu MC, Dubé LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol. 1996; 98(5 Pt 1): 859–871.
  12. Dicpinigaitis PV, Dobkin JB, Reichel J. Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J Asthma. 2002; 39(4): 291–297.
  13. Lipworth B. Leukotriene-receptor antagonists. The Lancet. 1999; 353(9146): 57–62.
  14. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999; 340(3): 197–206.
  15. Barnes NC, Miller CJ. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. Thorax. 2000; 55(6): 478–483.
  16. Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol. 2000; 105(6 Pt 1): 1123–1129.
  17. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med. 1999; 160(6): 1862–1868.
  18. Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J. 1998; 11(6): 1232–1239.
  19. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998; 339(3): 147–152.
  20. Löfdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999; 319(7202): 87–90.
  21. Virchow JC, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000; 162(2 Pt 1): 578–585.
  22. Price DB, Hernandez D, Magyar P, et al. Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003; 58(3): 211–216.
  23. Vaquerizo MJ, Casan P, Castillo J, et al. CASIOPEA (Capacidad de Singulair Oral en la Prevencion de Exacerbaciones Asmaticas) Study Group. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003; 58(3): 204–210.
  24. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ. 2003; 327(7420): 891.
  25. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol. 2000; 106(6): 1088–1095.
  26. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest. 2001; 120(2): 423–430.
  27. Ringdal N, Eliraz A, Pruzinec R, et al. International Study Group. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med. 2003; 97(3): 234–241.
  28. Cruz AA, Popov T, Pawankar R, et al. ARIA Initiative Scientific Committee. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy. 2007; 62 Suppl 84: 1–41.
  29. Mastalerz L, Gawlewicz-Mroczka A, Nizankowska E, et al. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin Exp Allergy. 2002; 32(9): 1360–1365.
  30. Mastalerz L, Nizankowska E, Sanak M, et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest. 2002; 32(12): 949–955.
  31. Dahlén B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998; 157(4 Pt 1): 1187–1194.
  32. Szczeklik A, Niżankowska-Mogilnicka E, Sanak M. Hypersensitivity to aspirin and other NSAIDs: mechanisms, clinical presentation and management. In: Pichler WJ. ed. Drug Hypersensitivity. Karger, Basel 2007: 340–349.
  33. Josefson D. Asthma drug linked with Churg-Strauss syndrome. BMJ. 1997; 315(7104): 330.
  34. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA. 1998; 279(6): 455–457.
  35. Franco J, Artés MJ. Pulmonary eosinophilia associated with montelukast. Thorax. 1999; 54(6): 558–560.
  36. Kinoshita M, Shiraishi T, Koga T, et al. Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. J Allergy Clin Immunol. 1999; 103(3 Pt 1): 534–535.
  37. Global Strategy for the Diagnosis, Managment, and Prevention of Chronic Obstrutive Pulmonary Disease. www.gold.cord.org (2007).
  38. Kozielski J, Chazan R, Gorecka D, et al. Diagnosis and therapy of chronic obstructive pulmonary disease-recommendations of the ish Phtisiopneumonology Society. Pneumonol Alergol Pol. 2002; 70(supl. 2): 2–42.
  39. Zühlke IE, Kanniess F, Richter K, et al. Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD. Eur Respir J. 2003; 22(6): 926–930.
  40. Nannini LJ, Flores DM. Bronchodilator effect of zafirlukast in subjects with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2003; 16(5): 307–311.
  41. Celik P, Sakar A, Havlucu Y, et al. Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir Med. 2005; 99(4): 444–450.
  42. Rubinstein I, Kumar B, Schriever C. Long-term montelukast therapy in moderate to severe COPD--a preliminary observation. Respir Med. 2004; 98(2): 134–138.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl